JUNO THERAPEUTICS INC's ticker is JUNO and the CUSIP is 48205A109. A total of 121 filers reported holding JUNO THERAPEUTICS INC in Q1 2015. The put-call ratio across all filers is 1.68 and the average weighting 1.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2017 | $15,501,000 | +11.9% | 339,112 | +9.8% | 0.00% | 0.0% |
| Q3 2017 | $13,856,000 | +64.5% | 308,880 | +9.6% | 0.00% | +100.0% |
| Q2 2017 | $8,425,000 | +44.5% | 281,858 | +7.3% | 0.00% | 0.0% |
| Q1 2017 | $5,832,000 | +21.0% | 262,801 | +2.8% | 0.00% | +100.0% |
| Q4 2016 | $4,819,000 | -32.9% | 255,636 | +6.9% | 0.00% | -50.0% |
| Q3 2016 | $7,178,000 | -27.9% | 239,187 | -7.7% | 0.00% | -33.3% |
| Q2 2016 | $9,959,000 | +56.1% | 259,047 | +54.7% | 0.00% | +50.0% |
| Q1 2016 | $6,378,000 | -1.0% | 167,439 | +14.3% | 0.00% | 0.0% |
| Q4 2015 | $6,441,000 | +53.5% | 146,514 | +42.1% | 0.00% | +100.0% |
| Q3 2015 | $4,195,000 | +63.1% | 103,130 | +113.8% | 0.00% | 0.0% |
| Q2 2015 | $2,572,000 | -14.4% | 48,232 | -2.6% | 0.00% | 0.0% |
| Q1 2015 | $3,004,000 | +1051.0% | 49,527 | +890.5% | 0.00% | – |
| Q4 2014 | $261,000 | – | 5,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 25,948,799 | $1,132,937,000 | 100.00% |
| Biomark Capital Management Co. LLC | 1,602,562 | $70,465,000 | 85.76% |
| Omega Fund Management, LLC | 1,229,512 | $54,062,000 | 30.09% |
| Clarius Group, LLC | 218,942 | $9,626,000 | 2.93% |
| BB BIOTECH AG | 1,305,000 | $57,381,000 | 1.62% |
| Casdin Capital, LLC | 17,500 | $769,000 | 0.68% |
| Rock Springs Capital Management LP | 197,001 | $8,662,000 | 0.66% |
| BENNETT LAWRENCE MANAGEMENT L L C/NY | 38,850 | $1,708,000 | 0.55% |
| ArrowMark Colorado Holdings LLC | 383,749 | $16,873,000 | 0.46% |
| SUFFOLK CAPITAL MANAGEMENT LLC | 68,848 | $3,027,000 | 0.38% |